Name: Raynaud's: Usually Harmless, Sometimes a Warning, Managed by Keeping Warm
Creator: Realised
Published: 2026-06-01

Summary

Raynaud's phenomenon (the fingers or toes going white, then blue, then red in the cold or under stress) is in about nine cases out of ten the benign primary form — common, harmless, and managed first by keeping the WHOLE body warm and cutting the triggers, with drugs reserved for the severe minority and "circulation supplements" unsupported as a fix — but the whole clinical game is the primary-versus-secondary split, because the other roughly one in ten is secondary Raynaud's that can herald scleroderma or lupus, predate systemic disease by up to two decades, and cause digital ulcers and tissu

Why Moderate

Moderate Evidence because the entry's verdict blends claims of different strength, and the load-bearing ones sit at Moderate. The primary-versus-secondary split and the red-flag list are high-confidence consensus (Strong for the split figures and the red-flag criteria), but the management claims that make the entry actionable are Moderate or below: the calcium-channel-blocker benefit rests on Cochrane low-to-moderate-quality RCTs with a modest effect; the whole-body-warming and trigger-avoidance first line is guideline consensus with under-trialled magnitude; and the supplement debunk rests on small, dated, inconsistent trials (which is exactly why the debunk is safe, even though the underlying trials are weak). The entry inherits the confidence of its load-bearing therapeutic claims, which is Moderate.

NOT Foundational because there is no single undisputed axiom — the entry carries clinical triage judgement and a live both-ways tension (benign primary versus dangerous secondary).

NOT Strong because the therapeutic anchors are not gold-standard: the drug benefit is modest and low-to-moderate quality, and the lifestyle magnitude is under-trialled. Only the diagnostic split and the red-flag criteria reach high confidence, and the entry marks those explicitly rather than letting them lift the whole verdict.

The per-claim split (read this, not just the headline):
• 90/10 primary-versus-secondary split; negative-antibody, young-symmetric primary pattern is low-risk: Strong (consensus across independent reviews).
• Red-flag criteria for secondary disease (older/male, ulcers, positive serology, abnormal capillaroscopy): Strong-to-Moderate (aligned academic and advocacy sources).
• Whole-body warming, smoking cessation, vasoconstrictor avoidance as first line: Moderate (guideline consensus, under-trialled magnitude).
• Calcium-channel blockers reduce attacks in severe cases: Moderate (Cochrane low-to-moderate quality, modest effect).
• Circulation supplements unsupported: the debunk is well-founded; the supplement trials themselves are Emerging-to-Experimental.

Practical takeaway

The framing to hold: first work out which Raynaud's this is, because the answer decides everything. Primary means reassure and keep warm; secondary means a workup. Do not skip that step.

Step one: is this primary or secondary?
• Reassuring (primary) pattern: young onset (often teens or twenties), more common in women, both hands affected symmetrically, no ulcers or tissue damage, otherwise well. This is common and benign.
• Warning (secondary) pattern: onset in an older adult or a man, asymmetry, digital ulcers or pitting scars or tissue loss, or other clues (joint, skin or reflux symptoms). This warrants assessment including antibody testing and nailfold capillaroscopy, not reassurance.

For primary Raynaud's, manage it without a drug first.
• Keep the WHOLE body warm. Layer the core and extremities, warm up before going into the cold, use gloves and warm footwear. Core warmth beats hands-only warming.
• Stop smoking. Tobacco directly worsens vasospasm.
• Cut the vasoconstrictors. Review with a clinician whether stimulants, non-selective beta-blockers, ergots or triptans can be avoided or swapped.
• Manage stress triggers. Sympathetic surges provoke attacks, so the general stress-load levers apply.

Escalate to a drug only for severe or function-limiting attacks.
• Calcium-channel blockers (nifedipine) are first-line pharmacologically, with a modest, real benefit (a few fewer attacks per week). Reserve them for frequent or severe attacks, and expect side effects (headache, flushing, ankle swelling, lowered blood pressure). This is a clinician decision, not a self-start.

Do not reach for "circulation supplements" as the fix. Ginkgo, fish oil, L-arginine and similar are unsupported as primary therapy: the trials are small, dated and inconsistent, and the enthusiastic framing comes mostly from sources that sell them.

Never treat secondary Raynaud's as "just keep warm." Warmth still helps the symptoms, but it is never a substitute for the workup and disease-directed care. A positive antibody, an abnormal capillary pattern, or a digital ulcer belongs with a rheumatologist.

Evidence detail

Why This Entry Exists

Raynaud's is a topic where the two failure modes point in exactly opposite directions, and getting the direction wrong is what causes harm. On one side, the benign primary form is over-medicalised and over-monetised: a young woman with cold-triggered colour changes and nothing else is common, low-risk, and needs warmth and trigger avoidance, not nifedipine and certainly not a "circulation supplement." On the other side, the far smaller secondary group is under-triaged: labelled as "just poor circulation," reassured, and sent home when the colour changes are the earliest visible sign of an underlying connective-tissue disease that will show up years later. The entry has to hold both truths at once, because the same word covers a nuisance and a warning sign.

The primary-versus-secondary distinction is not a footnote here. It is the entire clinical decision. Primary Raynaud's (young onset, symmetric, no other findings, negative antibodies, normal nailfold capillaries) means reassure and keep warm, escalating to a drug only if attacks are frequent or severe enough to threaten function. Secondary Raynaud's (older or male onset, asymmetry, digital ulcers, positive serology, an abnormal capillary pattern) means a workup, not reassurance, because the cost of missing incipient scleroderma is ulcers and tissue loss. Both the over-treat error and the under-triage error are real, and the split is what resolves both.

What bad advice this protects against, in all directions:
• "Raynaud's is nothing, everyone gets cold hands" → true for the primary form, dangerously wrong for the secondary form; new colour changes in an older adult or a man, or with ulcers or asymmetry, are a red flag for underlying autoimmune disease, not a quirk of circulation.
• "You need a drug for Raynaud's" → most primary cases never need one; whole-body warming and trigger avoidance handle it, and the drug evidence (calcium-channel blockers) is a modest benefit reserved for severe cases.
• "Take a circulation supplement to fix it" → ginkgo, fish oil, L-arginine and the rest are unsupported as primary therapy; the trials are small, dated, inconsistent, and the pro-supplement framing clusters in vendor sources that sell the product.
• "Just warm your hands" → the physiologically correct instruction is to keep the WHOLE body warm; core cooling drives the peripheral vasospasm, so hands-only warming misses the lever.
• "It's benign, no need to see anyone" → true only inside the primary pattern; a positive antibody test or an abnormal nailfold capillaroscopy changes the whole picture and belongs with a rheumatologist.
• "Secondary Raynaud's needs the same keep-warm advice" → warmth still helps symptoms, but it is never a substitute for the workup and disease-directed management; treating the vasospasm while ignoring the scleroderma is the dangerous move.

This entry owns the primary-versus-secondary verdict, the first-line management (whole-body warmth, trigger and drug avoidance), the drug evidence (calcium-channel blockers for severe cases), the supplement debunk, and the red-flag list. It defers deliberate cold exposure as a practice to deliberate_cold_exposure_stress, and actual cardiovascular management to cardiovascular_health_management. It states those boundaries and routes there rather than re-arguing them.

Evidence

Organised by the clinical decision, with the tier signal inline. The primary-versus-secondary split and the red-flag list are the firmest, most consequential parts; the drug benefit is real but modest; the supplement claims are weak, which is precisely why the debunk holds.

The split that decides everything: about nine in ten are benign primary, about one in ten are secondary.

1. Roughly 90% of Raynaud's is primary — no other abnormality, negative antibodies, onset often before age 20 — and about 10% is secondary, most commonly to systemic sclerosis. Raynaud's phenomenon is common, affecting an estimated 4–15% of adults and up to 20–30% of young women. In the secondary group, systemic sclerosis dominates: Raynaud's is present in roughly 90% of scleroderma and around 85% of mixed connective-tissue disease. Patients with isolated primary Raynaud's persisting for more than two years without new features are at low risk of turning out to have an autoimmune disease. (Wigley and Herrick narrative reviews, Rheumatic Disease Clinics via ScienceDirect; a pathogenesis/workup/treatment update in the Vascular Surgery-adjacent literature (vsijournal), 2020s. Strong Evidence for the split — the 90/10 figures and the negative-antibody gate are long-standing, guideline-level consensus across independent academic reviews, with no supplement or device conflict.)

2. The best predictor of who progresses to systemic sclerosis is the COMBINATION of a scleroderma pattern on nailfold capillaroscopy plus a scleroderma-specific autoantibody — this is a workup question, not a supplement question. In a Raynaud's population, the pairing of a "scleroderma pattern" on nailfold videocapillaroscopy (giant capillaries, microhaemorrhages, capillary dropout, typically fewer than 7–10 capillaries per millimetre) with a systemic-sclerosis-specific autoantibody (anti-centromere, anti-topoisomerase/Scl-70, or anti-RNA-polymerase III) is the strongest signal that vasospasm will evolve into systemic disease. This is the red-flag workup that separates reassurance from referral. (Cutolo et al., state-of-the-art nailfold videocapillaroscopy review, PMC8922564; Smith et al., capillaroscopy predictive reviews. Moderate — diagnostic-accuracy evidence from prospective cohorts; capillaroscopy is a low-cost imaging method from academic rheumatology, with minimal commercial incentive.)

Red flags for secondary Raynaud's: the demographic and the digits.

3. Onset in an older adult or a man, asymmetry, digital ulcers or pitting scars or tissue loss, positive antibodies, and an abnormal nailfold pattern are the urgent red flags — and vasospasm can predate systemic disease by up to about 20 years. The benign primary pattern is young, female, symmetric, and free of tissue damage. Anything outside that pattern warrants serology and capillaroscopy rather than reassurance, because Raynaud's can be the first visible sign of a connective-tissue disease that only declares itself years or decades later. Digital ulcers and tissue loss are the concrete cost of missing it. (ScienceDirect Rheumatic Disease Clinics review noting vasospasm can predate systemic disease by up to 20 years; the vsijournal diagnostic-workup update; scleroderma.org fact sheet on digital ulcers. Strong-to-Moderate consensus — patient-advocacy and academic sources align on the red-flag criteria, with no commercial skew on the list.)

First-line management is non-pharmacologic, and it works for many.

4. Keep the WHOLE body warm, stop smoking, and eliminate vasoconstrictor drugs and stimulants — drugs are reserved for when this is not enough. First-line management is behavioural: warming the core and not just the hands (core cooling drives the peripheral vasospasm), smoking cessation (tobacco directly worsens vasospasm), and removing vasoconstrictors — non-selective beta-blockers, ergot derivatives, triptans, amphetamines and other stimulants. Pharmacologic therapy is stepped up only when these measures are insufficient. (StatPearls, "Raynaud Disease," NCBI Bookshelf NBK499833; Cleveland Clinic Journal of Medicine, "Treating Raynaud phenomenon: Beyond staying warm," 2017;84(10):797; NHS inform. Moderate — guideline and consensus level; the whole-body-warming detail is physiologically correct and frequently missed, though the precise magnitude of the lifestyle benefit is under-trialled.)

The drug evidence: real but modest, for severe cases only.

5. Calcium-channel blockers (dihydropyridines, especially nifedipine) cut attack frequency and severity versus placebo, but the benefit is modest and the evidence quality is low-to-moderate. Meta-analysis found a reduction of roughly 2.8–5 attacks per week in primary Raynaud's, with higher doses more effective and more withdrawals for side effects, though none serious. This supports "a drug for severe cases," not routine use for everyone with cold hands. (Cochrane reviews: Rirash et al. 2017, CD000467.pub2, calcium-channel blockers for primary and secondary Raynaud's; Ennis et al. 2014, CD002069.pub4, for primary Raynaud's; Thompson and Pope meta-analysis, Rheumatology 2005;44(2):145. Moderate — Cochrane-graded low-to-moderate-quality RCT evidence. Nifedipine is off-patent and generic, so there is little industry incentive to inflate its effect; if anything, calcium-channel blockers are under-promoted relative to newer patented agents.)

The supplement claims: weak, dated, and vendor-skewed — the debunk is well-founded.

6. "Circulation supplements" are unsupported as primary therapy. Ginkgo biloba: one small double-blind placebo-controlled trial reduced attack frequency, but not severity or duration, in primary Raynaud's, and a later, larger comparison found it inferior to nifedipine. Fish oil: a small trial reduced cold reactivity in PRIMARY Raynaud's only, with no benefit in the secondary form. Modern reviews conclude there is biological plausibility but no high-quality evidence, and do not recommend routine use. (Muir et al., Vascular Medicine 2002;7(4):265, the ginkgo double-blind placebo-controlled trial; the later ginkgo-versus-nifedipine comparison registered as ClinicalTrials.gov NCT00251238; the DiGiacomo fish-oil trial; 2020s reviews concluding supplements lack high-quality RCT support. Emerging-to-Experimental for the supplements — small, dated, inconsistent trials, i.e. the debunk is well-founded. Cui bono: the pro-supplement framing concentrates in vendor sources such as ConsumerLab and Life Extension, which sell the products; the independent trial and review literature declines to recommend them — a classic oversold-consumer-claim over weak-real-mechanism gap.)

Mechanism

This entry owns the clinical decision and the management, not a full vascular-physiology treatise. What follows is only enough mechanism to make the split, the warming instruction, and the drug rationale intelligible.

Why cold and stress turn the fingers white, then blue, then red. Raynaud's is exaggerated vasospasm of the small arteries and arterioles of the digits. A cold stimulus or sympathetic surge (stress) clamps the vessels shut, blanching the finger white; the trapped, deoxygenated blood turns it blue; and when flow returns, reactive hyperaemia flushes it red. In the primary form this is an over-brisk but structurally normal vascular response. In the secondary form the vessels are also structurally abnormal (the capillary changes seen on nailfold capillaroscopy), which is why secondary disease can progress to fixed ischaemia, ulcers, and tissue loss rather than just transient colour change.

Why "keep the whole body warm," not just the hands. Peripheral vasoconstriction is driven substantially by core temperature and central sympathetic tone, not only by local finger temperature. When the body's core cools, it defends central warmth by shutting down peripheral flow, and the digits pay the price. This is why warming the trunk, wearing layers, and avoiding whole-body cold exposure does more than a pair of gloves alone, and it is the single most frequently missed practical instruction.

Why smoking, stimulants and certain drugs make it worse. Anything that raises sympathetic vasoconstrictor tone or directly constricts vessels amplifies the attack: nicotine and tobacco, amphetamines and stimulants, ergot derivatives, triptans, and non-selective beta-blockers. Removing these is mechanistically first-line because it takes a foot off the constrictor pedal.

Why calcium-channel blockers are the drug of choice, and why the effect is only modest. Dihydropyridine calcium-channel blockers (nifedipine) relax vascular smooth muscle and promote vasodilation, directly opposing the vasospasm. The mechanism is clean, which is why they are first-line pharmacologically. But they cannot fix the structural vessel abnormality of secondary disease, and even in primary disease they only blunt the attacks, which is why the measured benefit is a few fewer attacks per week rather than a cure.

Why the supplements are plausible but unproven. The "circulation supplement" pitch leans on vasodilatory or antioxidant mechanisms (ginkgo, L-arginine as a nitric-oxide substrate, omega-3s on membrane and endothelial function). Each has a plausible story, which is exactly why the products sell. But a plausible mechanism is not a demonstrated clinical outcome, and the small trials that exist do not show a reliable, meaningful reduction in both frequency and severity. Mechanism explains why people try them; it does not establish that they work.

Risks And Contraindications

• The load-bearing safety item: missing SECONDARY Raynaud's. This is the dominant risk in the whole topic. Secondary Raynaud's can be the earliest visible sign of scleroderma or lupus, predating systemic disease by up to about two decades, and it causes digital ulcers, pitting scars, and tissue loss. Onset in an older adult or a man, asymmetry, ulcers or tissue damage, a positive ANA or scleroderma-specific antibody, and an abnormal nailfold capillaroscopy are red flags that demand rheumatology assessment. Labelling this "poor circulation, keep warm" and reassuring the patient is the dangerous error. When the pattern is not the young, symmetric, otherwise-well primary picture, refer for serology and capillaroscopy — do not reassure.
• Over-treatment of benign primary Raynaud's. Prescribing nifedipine for mild, primary cold-hands imposes dose-dependent headache, flushing, ankle oedema, and hypotension for a condition that warmth and trigger avoidance would manage. Match the intervention to the severity.
• Selling supplements for a benign, self-limiting condition. "Circulation supplements" cost money, carry their own interaction and quality risks, and are unsupported as primary therapy; recommending them substitutes a purchase for the free, effective first-line measures.
• Do not oversell the drug. The calcium-channel-blocker benefit is genuinely modest — roughly 2.8–5 fewer attacks per week (Thompson and Pope 2005, Rheumatology 44(2):145), and the Cochrane primary-Raynaud's review (Ennis, CD002069) puts it more modestly still at around 1.7 attacks per person per week, grading calcium-channel blockers "minimally effective." It reduces attacks; it does not abolish the condition or fix secondary vessel damage.
• Do not give warmth or nifedipine as a substitute for the red-flag workup in the wrong demographic. Symptom management and diagnostic assessment are not interchangeable; in a secondary-pattern patient, do both, and never let the first replace the second.
• Avoid the opposite over-correction. "Raynaud's is always benign" is as wrong as "Raynaud's always means disease." The honest message is: usually benign, sometimes a warning, and the split tells you which.

Controversy

Nature: a single label that covers two very different things — a common, benign nuisance (primary) and an early warning sign of serious autoimmune disease (secondary) — with error possible at both poles: over-treating and over-monetising the benign form on one side, and under-triaging the dangerous form on the other.

Position A — "Primary Raynaud's is common, benign, and managed by keeping warm." The reassure-and-manage take.
• Best evidence: about nine in ten cases are primary, with negative antibodies, young symmetric onset, and no tissue damage; most need no drug at all, only whole-body warmth and trigger avoidance; and where a drug is warranted, an off-patent calcium-channel blocker gives a modest benefit. "Circulation supplements" are unsupported.
• Where it goes wrong if overstated: it slides into "all cold hands are nothing," dismisses the secondary red flags, and reassures a patient who actually needs a workup.

Position B — "The opposite errors matter: don't miss secondary Raynaud's, and don't sell supplements." The vigilance-and-honesty take.
• Best evidence: secondary Raynaud's can herald scleroderma or lupus, predate systemic disease by up to 20 years, and cause digital ulcers and tissue loss; older or male onset, asymmetry, ulcers, positive serology and abnormal capillaroscopy are red flags; and the supplement market is unsupported by high-quality trials.
• Where it goes wrong if overstated: it can tip into over-medicalising every young woman with cold fingers, ordering unnecessary antibody panels, and prescribing drugs for a benign condition.

The funding/bias dimension — cui bono, both ways. Toward over-selling supplements: the pro-supplement framing concentrates in vendor-run sources (ConsumerLab, Life Extension) that profit from ginkgo, fish oil, niacin and L-arginine sold as "circulation" fixes, while the independent trial and review literature declines to recommend them. Toward the drug side, the incentive runs the other way: nifedipine is generic and unpromoted, so the well-evidenced, cheap first-line drug is under-marketed relative to newer patented agents (PDE5 inhibitors, prostacyclin analogues, endothelin antagonists) aimed at severe and secondary disease. The red-flag criteria and the 90/10 split come from conflict-clean academic and patient-advocacy sources.

Realised Position: The primary-versus-secondary distinction is the entire clinical decision, and it resolves both errors. Primary Raynaud's (negative antibodies, young symmetric onset, normal capillaroscopy) means reassure and keep the whole body warm, escalating to nifedipine only if attacks are severe. Secondary red flags (older or male onset, digital ulcers, positive serology, abnormal capillaroscopy) mean an urgent workup, never "just keep warm." Both the over-treat error (drugs or supplements for benign primary) and the under-triage error (missing scleroderma) are real. Whole-body warmth and trigger avoidance are the free, effective first line; the calcium-channel blocker is a modest adjunct for severe cases; and the "circulation supplement" market is an unsupported over-claim to correct, not endorse.

Cross-Pillar Connections

Raynaud's is a cross-pillar vascular-and-autoimmune topic, so its connections span the cardiovascular, cold-exposure, endocrine, immune and evidence lines.
• Conditions (cardiovascular_health_management): owns actual cardiovascular and vascular management; this entry holds only the Raynaud's-specific triage and first-line measures and defers broader vascular care there.
• Physical / practice (deliberate_cold_exposure_stress): owns cold exposure as a deliberate practice; relevant because cold is the primary trigger for Raynaud's attacks, so the two entries pull in opposite directions for this population — cold exposure is a hazard, not a tool, for someone with Raynaud's.
• Metabolic/Hormonal (thyroid_dysfunction): hypothyroidism is one of the systemic conditions associated with cold intolerance and secondary vasospastic symptoms, and part of the differential when cold hands sit alongside other systemic features.
• Conditions (immune_function_cross_pillar_optimisation): the immune/autoimmune context for why secondary Raynaud's heralds connective-tissue disease — the reason the red flags matter.
• Foundations (publication_bias_and_evidence_distortion): the mechanism behind the selective, vendor-skewed supplement framing and the neglect of the unpromoted generic drug.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd upgrade the supplement claim from "unsupported" to conditional if a large, well-powered, modern RCT showed a "circulation supplement" (ginkgo, omega-3, or L-arginine) delivering a clinically meaningful reduction in attack frequency AND severity in primary Raynaud's. The current trials are small, dated, and inconsistent, and no single one shows both.
• We'd tighten the reassurance threshold for primary Raynaud's if evidence showed that isolated primary disease with negative antibodies and normal capillaroscopy carried a meaningful undetected connective-tissue-disease risk — i.e. that the current "low-risk after two years" reassurance is unsafe. Right now the reassurance is well-supported.
• We'd revise the treat-versus-reassure line on the drug if a head-to-head trial showed calcium-channel blockers offering substantially more than the modest few-attacks-per-week benefit, or that whole-body warming underperforms drugs even in mild disease. The current evidence says the drug is a modest adjunct, not a first move for mild cases.
• What would NOT move us: the existence of the secondary red flags, the value of whole-body (not hands-only) warming, or the fact that generic nifedipine is under-marketed relative to shiny patented agents — the bias vector on the supplement side runs toward over-claiming, and on the drug side toward under-promoting the cheap effective option.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs in two opposite directions here, and naming both is the point.
• The supplement industry frames Raynaud's as a "circulation" problem it can sell into. Ginkgo, fish oil, niacin and L-arginine are marketed as circulation fixes, and in these searches the pro-supplement content clustered in vendor-run sources (ConsumerLab, Life Extension) that profit from the sale. The independent trial and review literature does not recommend them — a classic oversold-consumer-claim over weak-real-mechanism gap (see publication_bias_and_evidence_distortion).
• The pharma incentive runs the OTHER way for first-line therapy. Nifedipine is off-patent and generic, so no one promotes it. The well-evidenced, cheap, guideline first-line drug is therefore under-marketed relative to newer patented agents (PDE5 inhibitors, prostacyclin analogues, endothelin antagonists) that target severe and secondary disease and carry real promotional budgets. The commercial pressure pushes attention toward the shiny new molecule and away from the boring generic that is actually first-line.
• The diagnostic and red-flag literature is conflict-clean. The 90/10 split, the negative-antibody primary gate, the capillaroscopy-plus-antibody predictor, and the red-flag list come from academic rheumatology and patient-advocacy sources with no product to sell. That is exactly why they are the load-bearing, trustworthy claims in the entry.
• Net: correct the supplement over-claim, and note explicitly that the boring generic drug — not the newest patented agent — is the guideline first-line pharmacologic. The bias vector is not one-directional here: it inflates supplements on one side and neglects the cheap effective drug on the other.

Raynaud's: Usually Harmless, Sometimes a Warning, Managed by Keeping Warm